R

    Royalty Pharma Plc (RPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $61.41
    +0.56 (+0.92%)

    Market Cap: $35.16B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(27/30)
    Avg Surprise
    +30.84%
    Streak
    8 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$1.17
    Range$1.14 - $1.22
    6 analysts
    EPS Revisions
    3
    0
    7d
    3
    1
    30d
    EPS Estimate Drift
    90d ago$1.13-3.5%
    60d ago$1.13-3.5%
    30d ago$1.14-2.8%
    7d ago$1.13-3.5%
    Current$1.17
    Revenue Consensus
    $877M
    Range$855M - $892M
    4 analysts
    Dec 31, 2026
    EPS Consensus$1.70
    Range$1.65 - $1.81
    6 analysts
    Revenue Consensus
    $986M
    Range$950M - $1.0B
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.70---
    Sep 26EST
    		-$1.17---
    Jun 26
    		$1.32$1.27+3.94%Beat+15.8%
    Mar 26
    		$1.30$1.18+10.17%Beat+22.6%
    Dec 25
    		$1.47$1.33+10.53%Beat+27.8%
    Sep 25
    		$1.17$1.11+5.41%Beat+12.5%
    Jun 25
    		$1.14$1.03+10.68%Beat+18.7%
    Mar 25
    		$1.06$0.95+11.58%Beat+8.2%
    Dec 24
    		$1.15$1.05+9.52%Beat-24.3%
    Sep 24
    		$1.04$0.93+11.83%Beat+31.6%
    Jun 24
    		$0.96$0.97-1.03%Miss+14.3%
    Mar 24
    		$0.98$0.98+0.00%Beat-38.8%
    Dec 23
    		$1.52$1.00+52.00%Beat-2.6%
    Sep 23
    		$0.79$0.77+2.60%Beat+8.2%
    Jun 23
    		$0.84$0.81+3.70%Beat+6.3%
    Mar 23
    		$1.60$1.27+25.98%Beat+166.7%
    Dec 22
    		$1.56$1.46+6.85%Beat+95.0%
    Sep 22
    		$0.73$0.71+2.82%Beat+0.0%
    Jun 22
    		$0.79$0.78+1.28%Beat+11.3%
    Mar 22
    		$0.60$0.72-16.67%Miss-10.4%
    Dec 21
    		$0.80$0.78+2.56%Beat+14.3%
    Sep 21
    		$0.73$0.70+4.29%Beat+12.3%
    Jun 21
    		$0.71$0.71+0.00%Beat+16.4%
    Mar 21
    		$0.67$0.65+3.08%Beat-83.0%
    Dec 20
    		$0.70$0.70+0.00%Beat+1500.0%
    Sep 20
    		$0.65$0.59+10.17%Beat+912.5%
    Jun 20
    		$0.61$0.60+1.67%Beat+377.3%
    Mar 20
    		$3.94$0.52+657.69%Beat+2562.5%
    Sep 17
    		$-0.05N/A+82.14%Beat-
    Jun 17
    		$-0.08N/A+63.64%Beat-
    Mar 17
    		$-0.22$-0.14-57.14%Miss-
    Dec 16
    		$-0.16$-0.17+5.88%Beat-

    Dividends

    Dividend Metrics

    Yield1.51%
    Annual/Share$0.93
    Payout Ratio30.50%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+5.01%
    View RPRX's full dividend history

    Key Metrics

    Valuation
    P/E Ratio11.67EV/EBITDA20.32x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin32.00%Operating Margin19.80%
    ROE14.00%ROIC8.20%
    Financial Health
    Debt/Equity1.31xInterest Coverage4.54x
    Current Ratio2.80xQuick Ratio2.80x
    Trading Statistics
    Beta0.42Avg Volume2.73M
    52-Week High$62.4552-Week Low$33.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$61.27
    SMA 20$59.58
    SMA 50$58.06
    SMA 200$48.46
    EMA 10$60.98
    EMA 20$60.10
    EMA 50$58.07
    EMA 200$50.03

    MACD

    Line: 1.13Signal: 1.04Hist: 0.09

    ADX

    ADX: 30.8+DI: 24.1-DI: 12.8

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down24.0
    PSAR$59.63

    Bollinger Bands

    Upper Band$63.40
    Lower Band$55.77
    %B Position1280%(Upper)
    Band Width0.74

    RSI (14-Day)

    Neutral
    60.5

    Momentum Oscillators

    Stoch %K78.6
    Stoch %D84.0
    Williams %R-21.7
    ROC (10d)3.3%
    Momentum1.96
    CCI (20d)64.8
    MFI (14d)57.1

    Volatility Measures

    ATR (14d)$1.36(2.2%)
    StdDev (20d)1.91
    Hist Vol21.7%(Moderate)

    Volume Flow

    VWAP$61.17
    OBV336.3M
    AD Line-1.9B
    CMF (20d)-0.057

    Volume Metrics

    Avg Vol (20d)2.7M
    Vol Ratio1.3x
    VWMA (20d)$59.30

    Pivot Points

    R3$63.04
    R2$62.53
    R1$61.69
    Pivot Point$61.17
    S1$60.33
    S2$59.82
    S3$58.98

    Advanced Oscillators

    TSI23.14
    Ultimate Osc58.2
    KST56.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$674.14M$630.58M$621.99M$609.29M$578.66M$568.25M$593.64M$564.69M$537.27M$567.98M$596.07M$536.31M
    Cost of Revenue$0$0$1.20M$0$0$0$164.04M$0$0$0$76.51M$0
    Gross Profit$674.14M$630.58M$621.99M$609.29M$578.66M$568.25M$593.64M$564.69M$537.27M$567.98M$596.07M$536.31M
    Operating Expenses$541.02M$67.54M$233.61M$182.13M$368.87M$34.06M$232.13M$-170,384,000$267.64M$641.75M$-16,828,000$384.87M
    R&D$97.85M$39.79M$50.50M$50.50M$300.50M$50.50M$500,000$500,000$500,000$500,000$500,000$50.50M
    SG&A$161.89M$159.49M$164.27M$118.73M$179.77M$110.70M$67.59M$56.72M$54.71M$57.65M$59.19M$57.23M
    Operating Income$133.12M$563.04M$388.38M$427.16M$209.80M$534.18M$361.51M$735.07M$269.63M$-73,774,000$612.90M$151.44M
    Interest Income$9.20M$27.99M$11.08M$22.85M$11.02M$17.73M$40.69M$27.91M$15.08M$-6,732,000$6.77M$18.21M
    Interest Expense$93.62M$93.72M$94.17M$79.56M$68.67M$65.26M$65.76M$66.51M$49.01M$44.23M$47.26M$46.03M
    Income Before Tax$81.49M$468.26M$355.91M$444.21M$92.64M$434.43M$334.35M$806.36M$194.38M$-4,273,000$717.59M$122.08M
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$81.49M$468.26M$355.91M$444.21M$92.64M$434.43M$334.35M$806.36M$194.38M$-4,273,000$717.59M$122.08M
    EBITDA$165.90M$533.99M$439.01M$500.92M$150.28M$481.96M$359.43M$844.95M$228.31M$46.69M$758.07M$149.90M
    EBIT$165.90M$533.99M$439.01M$500.92M$150.28M$481.96M$359.43M$844.95M$228.31M$46.69M$758.07M$149.90M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RPRX

    News

    RPRX | Royalty Pharma plc Class Financials - Revenue Breakdown

    This article provides a detailed financial overview of Royalty Pharma plc (RPRX), focusing on its revenue breakdown and other key financial metrics. It includes sections on insider trading, institutional holdings, analyst ratings, and information about the company's business model as the largest buyer of biopharmaceutical royalties. The report highlights the absence of specific revenue breakdown by segment or geography, congressional trading data, corporate lobbying instances, and recent patent grants for RPRX.

    Quiver Quantitative•8/23/26•
    Neutral

    Royalty Pharma (NASDAQ: RPRX) exec sells 100K shares, donates stock

    Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma (RPRX), reported insider activity including the sale of 100,000 Class A Ordinary Shares by an associated entity, SCH Investment Partners LLC, at a weighted average price of $59.9725 per share. The sale was executed under a Rule 10b5-1 trading plan. Additionally, Hite made a charitable gift of 16,800 Class A Ordinary Shares to Lehigh University, impacting his direct and indirect holdings in the company.

    Stock Titan•8/20/26•
    Somewhat-Bearish

    Royalty Pharma EVP Christopher Hite Sells 100,000 Shares and Donates 16,800 Shares to Charity

    Christopher Hite, EVP and Chairman of Partnering at Royalty Pharma plc, sold 100,000 Class A Ordinary Shares for approximately $5.99 million under a 10b5-1 trading plan. Additionally, he donated 16,800 shares to Lehigh University. Following these transactions, Hite retains significant direct and indirect ownership in the company.

    Kalkine Media•8/19/26•
    Neutral

    Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale

    SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma (NASDAQ: RPRX) with an aggregate market value of $6,012,000. These shares were acquired in private transactions in 2024 and 2025 and represent a small fraction of Royalty Pharma's 445,277,344 outstanding shares. The planned sale is part of a pre-arranged selling plan dated March 20, 2026, intended to comply with Rule 10b5-1(c), and follows previous sales by SCH Investment Partners LLC in June 2026.

    Stock Titan•8/18/26•
    Neutral

    Pablo Legorreta's 101.8M-share Royalty Pharma (NASDAQ: RPRX) stake updated

    Pablo Legorreta has updated his beneficial ownership in Royalty Pharma (NASDAQ: RPRX) through an amended SEC filing, reporting a stake of 101.8 million Class A shares, representing 18.73% of the class. This includes shares issuable under an A&R Exchange Agreement, and the recalculation follows a change in the number of outstanding Class A shares. The filing also details recent equity transactions, including the acquisition of shares from performance awards and a gift of partnership interests.

    Stock Titan•8/18/26•
    Neutral

    Frequently Asked Questions About RPRX

    What is RPRX's current dividend yield?
    Royalty Pharma Plc (RPRX) has a current dividend yield of 1.51%.
    Does RPRX pay dividends?
    Yes, Royalty Pharma Plc pays dividends with a current yield of 1.51%.
    What is RPRX's P/E ratio?
    Royalty Pharma Plc has a price-to-earnings (P/E) ratio of 11.67.
    What is RPRX's market cap?
    Royalty Pharma Plc (RPRX) has a market capitalization of $35.16B with a current stock price of $61.41.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In